Moderate to Severe Atopic Dermatitis Study

This study is currently closed to enrollment.

Controlled Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients with Moderate-to-Severe Atopic Dermatitis

AGE: 18-55 years old
SEX AT BIRTH: All

TYPE: Investigational Treatment Study
CONDITION: Atopic Dermatitis (Eczema)

HEALTHY PARTICIPANTS: No
LOCATION: UH Cleveland Medical Center

Study Purpose

The purpose of this study is to evaluate the impact of lebrikizumab on vaccine responses (TDaP and meningococcal) in patients with moderate-to-severe Atopic Dermatitis. This study will further assess the efficacy and safety of lebrikizumab in patients with AD.

STUDY ID#

STUDY20201892